Investor Relations

Investor Overview

Targeted Medical Pharma, Inc. (TRGM) a publicly traded, United States based medical nutrition company that develops amino acid based medical foods and other oral nutrition products for the long term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders.

The Company manufactures 8 proprietary amino acid based medical foods along with the dietary supplements Grotrexa (Japan), AppTrim (Japan), Hypertensa® Advanced and Clearwayz. Each product uses Targeted Cellular Technology, the Company's patented micro-nutrient delivery system that improves the absorption and cellular utilization of amino acids, nutrients and neurotransmitters. The products are manufactured in the United States and sold directly to physicians, pharmacies and patients in the United States, Japan, New Zealand, Ukraine, Russia and China.

The Company currently partners with organizations in Hong Kong, Ukraine, New Zealand, Japan and Russia for the development and distribution of products using the patented core ingredient technology. Targeted Medical Pharma is always looking for new domestic and international partners to develop and distribute pharmacologic, amino acid and nutrient based therapies for patients who cannot tolerate the dangerous side effects of certain drug therapies.

The Company is committed to delivering long-term value to investors by maintaining disciplined cost controls, optimizing capital investment and adhering to the highest standards of corporate governance.

 

Recent News read more

Register for Helpful Investor Information

Investor Relations Contact

William Horne
CFO
Targeted Medical Pharma
info@tmedpharma.com
(310) 474-9809

Automatic Notifications

Dr. Silver Interview - The Big Business of Falling Asleep on CNBC

Watch "The Big Business of Falling Asleep" on CNBC featuring Dr. Silver, Chief Medical Officer at Targeted Medical Pharma.